Tumor Biology

, Volume 33, Issue 1, pp 121–129 | Cite as

CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function

  • Jahyang Choi
  • Beomseok Suh
  • Yong-Oon Ahn
  • Tae Min Kim
  • Jeong-Ok Lee
  • Se-Hoon Lee
  • Dae Seog Heo
Research Article

Abstract

Myeloid-derived suppressor cells (MDSCs) are a subpopulation of myeloid cells with immunosuppressive function whose numbers are increased in conditions such as chronic infection, trauma, and cancer. Unlike murine MDSCs defined as CD11b+/Gr-1+, there are no specific markers for human MDSCs. The goal of this study was to delineate a specific human MDSCs subpopulation in granulocytes from terminal cancer patients and investigate its clinical implications. Here, we show that the CD15+/CD16low subset was increased in terminal cancer patients compared with healthy donors (P = 0.009). Phorbol 12-myristate 13-acetate-activated granulocytes (CD16low/CD66b++/CD15+) that have a phenotype similar to MDSCs from cancer patients, effectively suppressed both proliferation and cytotoxicity of normal T cells. Among cancer patients, T-cell proliferation was highly suppressed by granulocytes isolated from terminal cancer patients with a high proportion of CD15+/CD16low cells. Patients with low peripheral blood levels of CD15+/CD16low cells had significantly longer survival than those with high levels (P = 0.0011). Patients with higher levels of CD15+/CD16low also tended to have poor performance status (P = 0.05). These data suggest that CD15+/CD16low granulocytes found in terminal cancer patients may play a role in the progression of cancer by inhibiting tumor immunity.

Keywords

MDSCs CD15+/CD16low granulocytes T-cell suppression Tumor immunity Immune monitoring 

References

  1. 1.
    Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 2001;61(12):4756–60.PubMedGoogle Scholar
  2. 2.
    Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte–macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25(18):2546–53.PubMedCrossRefGoogle Scholar
  3. 3.
    Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007;13(2 Pt 2):721s–6s.PubMedCrossRefGoogle Scholar
  4. 4.
    Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166(1):678–89.PubMedGoogle Scholar
  5. 5.
    Srivastava MK, Bosch JJ, Thompson JA, Ksander BR, Edelman MJ, Ostrand-Rosenberg S. Lung cancer patients’ CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother. 2008;57(10):1493–504.PubMedCrossRefGoogle Scholar
  6. 6.
    Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology. 2008;135(1):234–43.PubMedCrossRefGoogle Scholar
  7. 7.
    Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol. 2010;22(2):238–244Google Scholar
  8. 8.
    Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5(8):641–54.PubMedCrossRefGoogle Scholar
  9. 9.
    Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol. 2002;168(2):689–95.PubMedGoogle Scholar
  10. 10.
    Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004;172(2):989–99.PubMedGoogle Scholar
  11. 11.
    Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69(4):1553–60.PubMedCrossRefGoogle Scholar
  12. 12.
    Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005;65(8):3044–8.PubMedGoogle Scholar
  13. 13.
    Dransfield I, Buckle AM, Savill JS, McDowall A, Haslett C, Hogg N. Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma RIII) expression. J Immunol. 1994;153(3):1254–63.PubMedGoogle Scholar
  14. 14.
    Munder M, Mollinedo F, Calafat J, Canchado J, Gil-Lamaignere C, Fuentes JM, et al. Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood. 2005;105(6):2549–56.PubMedCrossRefGoogle Scholar
  15. 15.
    Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49–59.PubMedCrossRefGoogle Scholar
  16. 16.
    Apolloni E, Bronte V, Mazzoni A, Serafini P, Cabrelle A, Segal DM, et al. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J Immunol. 2000;165(12):6723–30.PubMedGoogle Scholar
  17. 17.
    Homburg CH, de Haas M, von dem Borne AE, Verhoeven AJ, Reutelingsperger CP, Roos D. Human neutrophils lose their surface Fc gamma RIII and acquire Annexin V binding sites during apoptosis in vitro. Blood. 1995;85(2):532–40.PubMedGoogle Scholar
  18. 18.
    Brannigan AE, O’Connell PR, Hurley H, O’Neill A, Brady HR, Fitzpatrick JM, et al. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock. 2000;13(5):361–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Sayeed MM. Delay of neutrophil apoptosis can exacerbate inflammation in sepsis patients: cellular mechanisms. Crit Care Med. 2004;32(7):1604–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol. 2009;85(6):996–1004.PubMedCrossRefGoogle Scholar
  21. 21.
    Greifenberg V, Ribechini E, Rossner S, Lutz MB. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol. 2009;39(10):2865–76.PubMedCrossRefGoogle Scholar
  22. 22.
    Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell. 2008;14(5):408–19.PubMedCrossRefGoogle Scholar
  23. 23.
    Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182(8):4499–506.PubMedCrossRefGoogle Scholar
  24. 24.
    Ray P, Arora M, Poe SL, Ray A. Lung myeloid-derived suppressor cells and regulation of inflammation. Immunol Res. 2011;50(2–3):153–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111(8):4233–44.PubMedCrossRefGoogle Scholar
  26. 26.
    Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181(8):5791–802.PubMedGoogle Scholar
  27. 27.
    Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13(7):828–35.PubMedCrossRefGoogle Scholar
  28. 28.
    Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol. 2010;22(2):238–44.PubMedCrossRefGoogle Scholar
  29. 29.
    Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011;60(10):1419–30.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2011

Authors and Affiliations

  • Jahyang Choi
    • 1
    • 2
  • Beomseok Suh
    • 1
  • Yong-Oon Ahn
    • 1
    • 2
  • Tae Min Kim
    • 1
    • 2
    • 3
  • Jeong-Ok Lee
    • 1
    • 3
  • Se-Hoon Lee
    • 1
    • 2
    • 3
  • Dae Seog Heo
    • 1
    • 2
    • 3
  1. 1.Cancer Research InstituteSeoul National University College of Medicine and HospitalSeoulSouth Korea
  2. 2.Innovative Research Institute for Cell TherapySeoul National University College of Medicine and HospitalSeoulSouth Korea
  3. 3.Department of Internal MedicineSeoul National University College of Medicine and HospitalSeoulSouth Korea

Personalised recommendations